Corporate Update on Jiangsu Aoyang Health Industry Co., Ltd.
Jiangsu Aoyang Health Industry Co., Ltd. (002172.SZ) closed its trading session on Friday 23 November with no price change, reflecting a flat 0 % movement during the 24‑hour period that ended at 20:18 Central European Time. The current trading price of one share is approximately CNH 4.25 on the major Shenzhen exchanges, with a total circulating supply of 765.7 million shares. The company’s market capitalisation stands at CNH 536 million, while the volume of shares traded in the last 24 hours amounted to CNH 462 million.
Since the close of the previous month, Jiangsu Aoyang’s shares have declined by 14.58 %. The 200‑day simple moving average is at CNH 3.96, a level well below the current trading price. In the 52‑week range the stock’s highest valuation was CNH 6.27 on 22 September 2026, and its lowest was CNH 2.73 on 29 June 2026.
Pledge and Governance Shift
In a recent disclosure, Jiangsu Aoyang announced that its principal shareholder, Aoyang Group, has pledged approximately 2.7 % of the company’s shares. This pledge brings the holding’s coverage ratio near full exposure, raising questions about liquidity risk and long‑term governance. The announcement coincided with a sharp decline in the share price, which closed at its daily lower limit the day after the pledge was reported.
Aoyang Group’s controlling shareholder, Shen Xue‑ru, has been gradually divesting his stake in the company, transferring substantial portions of equity to third parties in the last few years. This exodus of a key investor, coupled with the recent pledge, has prompted scrutiny over who will ultimately steer the firm’s strategic direction.
Financial Performance and Balance‑Sheet Concerns
The company’s three‑year financial trend shows a clear downturn. Revenue and adjusted net profit have both fallen, while the debt‑to‑asset ratio has risen sharply. Moreover, short‑term liabilities now exceed the company’s liquid cash reserves, a situation that could constrain operational flexibility. Analysts note that these balance‑sheet pressures, combined with the shift in controlling interest, may force Jiangsu Aoyang to pursue more aggressive asset optimisation and operational revitalisation initiatives.
Comparative Market Activity
Over the same 24‑hour window, several peer stocks in the health and materials sectors exhibited diverse movements:
| Symbol | Recent % Change | Current Price | Market Cap (CNH/HKD) | P/E Ratio |
|---|---|---|---|---|
| 2530.HK (Numans Health Food) | +2.9 % | HKD 0.71 | HKD 690 million | 11.87 |
| 2667.HK (Beijing Tong Ren Tang Heal‑h) | –3.03 % | HKD 1.44 | HKD 691.1 million | 29.73 |
| 600880.SS (Chengdu B‑ray Media) | 0 % | CNH 3.90 | CNH 628.2 million | – |
| 600084.SS (Citic Niya Wine) | 0 % | CNH 4.20 | CNH 633.3 million | – |
| 002454.SZ (Songz Automobile Air Con) | 0 % | CNH 4.75 | CNH 629.9 million | 20.32 |
Songz Automobile Air Con recently released its third‑quarter 2026 financial report, providing updated performance metrics and forward‑looking guidance. The filing, available as a publicly accessible PDF, details the company’s operational outcomes and outlines key strategic initiatives aimed at sustaining growth and enhancing market competitiveness. The release focuses exclusively on the company’s own disclosures, without additional commentary or external analysis.
Company Profile
Jiangsu Aoyang Health Industry Co., Ltd. is headquartered in Zhangjiagang, China, and specializes in the production and marketing of chemical fiber products, including black fibers, flame‑retardant fibers, and long‑fiber bundles. In addition to its core materials business, the company engages in rehabilitation chains, health management, and related medical services. Listed on the Shenzhen Stock Exchange since its IPO on 27 September 2007, the firm maintains an online presence at www.ayjk.cn .
This article is intended to provide an objective overview of recent developments at Jiangsu Aoyang Health Industry Co., Ltd., contextualising the company’s market activity, governance changes, and financial trajectory within the broader sector.